C4 therapeutics and betta pharmaceuticals announce exclusive licensing agreement for the development and commercialization in greater china of cft8919, an orally bioavailable bidac™ degrader of egfr l858r for nsclc

C4 therapeutics to receive a $10 million upfront payment, a $25 million equity investment and is eligible to receive up to $357 million for development and commercial milestones plus royalties on net sales in greater china
CCCC Ratings Summary
CCCC Quant Ranking